Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;58(10):1143-1145.
doi: 10.1038/s41409-023-02025-0. Epub 2023 Jun 30.

Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma

Tamer Othman  1 , Robert Lowsky  2 , Carol Richman  1 , Rasmus Hoeg  1 , Mehrdad Abedi  1 , Joseph Tuscano  3
Affiliations

Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma

Tamer Othman et al. Bone Marrow Transplant. 2023 Oct.
No abstract available

PubMed Disclaimer

References

    1. Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, et al. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Adv. 2019;3:2454–64. https://doi.org/10.1182/bloodadvances.2019000297 . - DOI - PubMed - PMC
    1. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2022; https://doi.org/10.3324/haematol.2022.281242 .
    1. Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A, et al. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019;3:3062–9. https://doi.org/10.1182/bloodadvances.2019000593 . - DOI - PubMed - PMC
    1. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41:355–61. https://doi.org/10.1038/sj.bmt.1705919 . - DOI - PubMed
    1. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, et al. 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood. 2011;118:1132–9. https://doi.org/10.1182/blood-2010-12-324392 . - DOI - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources